Avid Bioservices (Avid Bioservices) Float Percentage Of Total Shares Outstanding : 83.82% (As of May. 18, 2024)

View and export this data going back to 1996. Start your Free Trial

What is Avid Bioservices Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Avid Bioservices's float shares is 53.21 Mil. Avid Bioservices's total shares outstanding is 63.48 Mil. Avid Bioservices's float percentage of total shares outstanding is 83.82%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Avid Bioservices's Insider Ownership is 2.53%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Avid Bioservices's Institutional Ownership is 40.28%.

Avid Bioservices Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Avid Bioservices's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	53.21	/	63.48
	=	83.82%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avid Bioservices (Avid Bioservices) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avid Bioservices Inc (NAS:CDMO) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

TEHN:Germany

Address

14191 Myford Road, Tustin, CA, USA, 92780

Website

https://www.avidbio.com

Avid Bioservices Inc is a clinical-stage biopharmaceutical company focused on the development and Current Good Manufacturing Practices (CGMP) of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development and high-quality CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries.

Executives

Matthew R. Kwietniak	officer: Chief Commercial Officer	14191 MYFORD ROAD, TUSTIN CA 92780
Richard A. Richieri	officer: Chief Operations Officer	14191 MYFORD ROAD, TUSTIN CA 92780
Daniel Ryan Hart	officer: Chief Financial Officer	2642 MICHELLE DR., SUITE 200, TUSTIN CA 62780
Mark R Ziebell	officer: V.P., General Counsel	14282 FRANKLIN AVENUE, TUSTIN CA 92780
Richard B Hancock	director	14282 FRANKLIN AVE., TUSTIN CA 92780
Joseph Carleone	director	3883 HOWARD HUGHES PKWY, SUITE 700, LAS VEGAS NV 89169
Nicholas Stewart Green	director, officer: President & CEO	2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Gregory Sargen	director
Esther M. Alegria	director	2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Mark R Bamforth	director	500 KENDALL ST., CAMBRIDGE MA 02142
Jeanne Thoma	director	C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623
Patrick D Walsh	director	14282 FRANKLIN AVE., TUSTIN CA 92780
Catherine J Mackey	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
Joel Mccomb	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Stephen Michael Hedberg	officer: Principal Fin. & Acct. Officer	2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780